Ring shaped contoured collagen shield for ophthalmic drug delivery

• US 7,985,208 B2
• Filed: 09/18/2008
• Issued: 07/26/2011
• Est. Priority Date: 09/18/2008
• Status: Expired due to Fees

• Current Assignee: Oasis Research LLC
• Original Assignee: Oasis Research LLC
• Inventors: Christensen, James M.
• Primary Examiner(s): Stephens; Jacqueline F
• Assistant Examiner(s): Craig; Paula L
• Application Number:
  US12/233,510
• Publication Number:
  US 20100069857A1
• Time in Patent Office: 1,041 Days
• Field of Search: 604/294, 604/300, 424/428, 424/429
• US Class Current: 604/294
• CPC Class Codes: A61F 2/14 Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2240/004 Using a positive or negative model, e.g. moulds
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: B29C 2035/0827 using UV radiation
• CPC Class Codes: B29C 35/0894 provided with masks or diaphragms

Abstract

A collagen corneal shield for placement on the outer surface of the eye for protection of the eye, for delivery of drugs to the eye, or for both protection and drug delivery to the eye, functions without obstructing vision. The shield has a first, central portion comprising non-crosslinked collagen capable of rapid decomposition in the presence of enzymes in the tears, and a second portion comprising crosslinked collagen which decomposes slowly in the presence of enzymes in the tears so that it remains on the eye for a period of time longer than the first portion. The first portion of the shield covers the central portion of the cornea and the second portion of the shield extends outward from the first portion. As a result of decomposition of the first portion the corneal shield becomes a ring or washer shape around the central portion and at least a portion of the cornea is no longer covered by the shield so that vision is not obstructed. The corneal shield can also be contoured so that it has one or more base curve radii selected to provide retention of the shield on the eye.

Claims

1. A device for placement on the outer surface of the eye to provide protection of the eye, delivery of drugs to the eye, or provide both protection and drug delivery to the eye, without obstructing vision, comprising

a) a contoured collagen shield with one or more base curve radii selected to provide retention of the shield on the eye, a first portion of the shield configured to cover a central portion of the cornea and a second portion of the shield extending outward from the first portion and forming a ring around the first portion,

b) the first portion of the shield comprising non-crosslinked collagen configured for rapid decomposition in the presence of enzymes in the tears, and

c) the second portion comprising crosslinked collagen having a decomposition rate in the presence of enzymes in the tears over a period of time slower than the first portion.

2. The device of claim 1 wherein the first portion of the shield once placed on the eye is substantially decomposed within about 1 to about 3 hours providing an opening in the shield over the central portion of the cornea.

3. The device of claim 1 wherein the cross linking of the second portions of the shield provides a predetermined resistance to enzymatic degradation once placed on the eye.

4. The device of claim 3 wherein the second portion of the shield has sufficient resistance to enzymatic degradation to remain on the eye from 24 hours to about 150 hours.

5. The device of claim 1 wherein the corneal shield has a dual radii base curve such that a portion of the shield covering the cornea has a base curve radius substantially equivalent to the radius of curvature of the cornea, and a second portion of the shield covering the sclera has a base curve radius substantially equivalent to the radius of curvature of the sclera.